LEADER 00976nam a2200277 i 4500 001 991004019729707536 005 20020509152639.0 008 930505s1991 uk ||| | eng 020 $a0521339294 035 $ab11249626-39ule_inst 035 $aPARLA193358$9ExL 040 $aDip.to Filol. Class. e Med.$bita 041 0 $aenggrc 082 0 $a938.05 100 1 $aRusten, Jeffrey S.$0171721 245 14$aThe Peloponnesian War :$bBook II /$cThucydides ; edited by J.S. Rusten 260 $aCambridge :$bCambridge University Press,$c1991 300 $aX, 262 p. ;$c19 cm. 490 0 $aCambridge greek and latin classics 650 4$aTucidide 907 $a.b11249626$b23-02-17$c01-07-02 912 $a991004019729707536 945 $aLE007 880.1 Thucydides 1991-01$g1$i2007000008270$lle007$o-$pE0.00$q-$rl$s- $t0$u1$v0$w1$x0$y.i11409654$z01-07-02 996 $aPeloponnesian War$9869058 997 $aUNISALENTO 998 $ale007$b01-01-93$cm$da $e-$feng$guk $h4$i1 LEADER 06352oam 2200445 450 001 9910822848903321 005 20190911100030.0 010 $a0-12-398252-9 035 $a(OCoLC)856624495 035 $a(MiFhGG)GVRL6OZJ 035 $a(EXLCZ)992660000000011059 100 $a20131227d2013 uy 0 101 0 $aeng 135 $aurun|---uuuua 181 $ctxt$2rdacontent 181 $csti$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aOsteoporosis /$fedited by Robert Marcus, MD, Professor Emeritus, Department of Medicine, Stanford University, Stanford, CA, USA [and four others] 205 $a4th ed. 210 $aAmsterdam ;$aBoston $cElsevier/AP$d2013 210 1$aOxford :$cAcademic Press,$d2013. 215 $a1 online resource (2 volumes (xxv, 2066 pages)) $cillustrations (some color) 225 0 $aGale eBooks 300 $aPrevious edition: 2008. 311 $a0-12-415853-6 320 $aIncludes bibliographical references and index. 327 $aV: 1 -- The bone organ system: form and function -- The nature of osteoporosis -- Reflections on osteoporosis -- Reflections on development of concepts of intercellular communication in bone -- Osteo-odyssey: a memoir -- Development of the skeleton -- The skeletal stem cell -- Osteoclast biology -- Osteoblast biology -- Osteocyte biology -- The regulatory role of matrix protein in mineralization of bone -- Parathyroid hormone and parathyroid hormone-related protein -- Vitamin D: biology, actions, and clinical implications -- Regulation of bone cell function by estrogens -- Androgens and skeletal biology: basic mechanisms -- Phosphatonins -- Skeletal growth factors -- Wnt signaling in skeletal homeostasis and diseases -- The mechanical behavior of bone -- Cellular and molecular mechanotransduction in bone -- Adaptation of skeletal structure to mechanical loading -- Biomechanics of hip and vertebral fractures -- Prevention of osteoporosis by physical signals: defining a potential role for nondrug strategies in the treatment of musculoskeletal injury and disease -- Epidemiologic methods in studies of osteoporosis -- Genetic determinants of osteoporosis -- Race, ethnicity, and osteoporosis -- Geographic variability in hip and vertebral fractures -- Nutrition and risk for osteoporosis -- Physical activity and exercise in the maintenance of the adult skeleton and the prevention of osteoporotic fractures -- Premenopausal reproductive and hormonal characteristics and the risk for osteoporosis -- Clinical and epidemiological studies: skeletal changes across menopause -- Osteoporosis in men: epidemiology, pathophysiology, and clinical characterization -- Falls as risk factors for fracture -- Nonskeletal risk factors for osteoporosis and fractures -- Outcomes following osteoporotic fractures -- Skeletal heterogeneity and the purposes of bone remodeling: implications for the understanding of osteoporosis -- On the evolution and contemporary roles of bone remodeling -- Cytokines and the pathogenesis of osteoporosis -- Animal models for osteoporosis -- Bone and fat -- Bone mineral acquisition in utero and during infancy and childhood -- Bone acquisition in adolescence. 327 $aV: 2 -- Osteoporosis in childhood and adolescence -- Osteoporosis associated with pregnancy -- Osteoporosis in premenopausal women -- Estrogen deficiency, postmenopausal osteoporosis, and age-related bone loss -- Immobilization osteoporosis -- Osteoporosis associated with illnesses and medications -- Glucocorticoid-induced osteoporosis -- Anticonvulsant-related bone disease -- Thyroid hormone and the skeleton -- The skeletal actions of parathyroid hormone in primary hyperparathyroidism and in osteoporosis -- Osteogenesis imperfecta and other defects of bone development as occasional causes of adult osteoporosis -- HIV and osteoporosis -- Obesity, diabetes, and fractures -- Osteoporosis in organ transplant patients -- Osteoporosis associated with rheumatologic disorders -- Osteoporosis associated with chronic kidney disease -- Oral bone loss and systemic osteoporosis: weighing the risk benefit ratio of treatment -- Cancer treatment-induced bone loss in patients with breast cancer: pathophysiology and clinical perspectives -- Pathophysiology-prostate cancer -- Mechanisms of bone destruction in myeloma -- Evaluation of the patient at risk for osteoporosis -- Imaging of osteoporosis -- Osteoporosis: who should be treated? Who should be screened? -- Clinical use of bone densitometry -- Biochemical markers of bone turnover in osteoporosis -- Fracture risk assessment: the development and application of FRAX® -- Orthopedic aspects of osteoporosis -- Falls prevention interventions -- Physical therapy, physical modalities, and exercise regimens in the management of osteoporosis -- Calcium in the treatment of osteoporosis -- Vitamin D and its metabolities and analogs in the management of osteoporosis -- Alternative therapy through nutrients and nutraceuticals -- Design considerations for clinical investigations of osteoporosis -- Lessons from bone histomorphometry on the mechanisms of action of osteoporosis drugs -- Estrogen and estrogen analogs for prevention and treatment of osteoporosis -- Androgens -- Calcitonin in osteoporosis -- Bisphosphonates: pharmacology and use in the treatment of osteoporosis -- Osteonecrosis of the jaw and atypical femoral fractures -- Condition critical: compliance and persistence with osteoporosis medications -- Denosumab for the treatment of osteoporosis -- Strontium ranelate in the prevention of osteoporotic fractures -- Parathyroid hormone treatment for osteoporosis -- New approaches to osteoporosis therapeutics -- The past, present, and uncertain future of therapeutic innovation in osteoporosis. 330 $aCovers everything from basic anatomy and physiology to diagnosis, management and treatment in which direct care costs for osteoporotic fractures in the United States reach up to $18 billion each year, continuing to make osteoporosis a critical challenge in medicine. 606 $aOsteoporosis 615 0$aOsteoporosis. 676 $a616.7/16 702 $aMarcus$b Robert$f1940- 801 0$bMiFhGG 801 1$bMiFhGG 906 $aBOOK 912 $a9910822848903321 996 $aOsteoporosis$91014999 997 $aUNINA